Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Diagnostics

Image: Guardant Reveal is a tissue-free liquid biopsy test that detects MRD and monitors recurrence in early-stage colorectal, breast, and lung cancers to help guide treatment decisions (Photo courtesy of Guardant Health)

Blood-Based MRD Test Predicts Recurrence Risk After Melanoma Surgery

A tissue-free liquid biopsy detects ctDNA MRD to predict melanoma recurrence earlier, with 81% sensitivity and 100% specificity. More...
07 Oct 2026
Image: Curve Biosciences’ Whole-Body Intelligence platform uses AI and the company\'s Whole-Body Atlas to uncover organ-specific biology from blood (photo courtesy of Curve Biosciences)

Blood Test Detects Molecular Signals of Early Liver Cancer Progression

A new blood test shows potential to monitor liver disease and detect very early HCC with 77.8% sensitivity, 81.5% specificity. More...
06 Oct 2026
Image: Haystack MRD is a tumor-informed, next-generation test that detects ultralow levels of ctDNA to identify residual or recurrent disease with high sensitivity and specificity (Photo courtesy of Quest Diagnostics)

Blood-Based MRD Test Shows High Specificity in Colorectal Cancer Trials

A tumor-informed ctdna liquid biopsy outperforms carcinoembryonic antigen (CEA) for detecting colorectal cancer recurrence More...
06 Oct 2026
Image: Personalized support increased BRCA testing uptake among at-risk relatives from 51% to 73% at six months, reaching 90% by 18 months (Image Credit: Adobe Stock)

Facilitated Cascade Program Increases Genetic Testing in Hereditary Cancer Families

New data show that facilitated family testing increases hereditary cancer testing uptake to 73–90%. More...
05 Oct 2026
Image: The test measures tumor-derived RNA in urine, capturing not only the presence of cancer but also which genes the tumor is actively using. (Image Credit: Shutterstock)

Urine-Based RNA Improves Bladder Cancer Detection and Monitoring

A new urine RNA test detects bladder cancer with 95% sensitivity and 90% specificity and predicts treatment response. More...
02 Oct 2026
Image: A set of 31 tiny RNA markers (small noncoding RNAs) could help identify people at higher lung cancer risk before the disease is clinically detected (Image Credit: 123RF)

Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis

An RNA-based blood panel flags lung cancer risk up to 10 years before diagnosis with 95% accuracy More...
01 Oct 2026
Image: Schematic overview of the obtained results. (Carla Rojo, María Rullan, Miguel Sogbe, et al. eGastroenterology, 2026. doi:10.1136/ egastro-2026-100425)

Bile DNA Testing Detects Tumor Signals Before Conventional Cancer Diagnosis

New data show that bile-based DNA analysis detects cancer in biliary strictures and is more specific than a standard blood marker. More...
01 Oct 2026
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Neonatal Heel Incision Device
Tenderfoot


Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.
Copyright © 2000-2026 Globetech Media. All rights reserved.